EFMH
SMMT icon

E Fund Management (HK)’s Summit Therapeutics SMMT Stock Holding History

E Fund Management (HK)’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4K Buy
1,334
+380
+40% +$6.74K 0.01% 322
2026
Q1 		$18.1K Buy
+954
New +$15.4K 0.01% 214

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

E Fund Management (HK)'s SMMT Position: Q2 2026 in Review

E Fund Management (HK) increased its Summit Therapeutics (SMMT) stake by 40% in Q2 2026, buying an estimated $6.74K and bringing the position to 1,334 shares worth $19.4K. The position accounts for 0.01% of the portfolio, ranked #322.

E Fund Management (HK) first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • E Fund Management (HK) held 1,334 shares of Summit Therapeutics worth $19.4K as of Q2 2026.
  • E Fund Management (HK) bought 380 Summit Therapeutics shares in Q2 2026, an estimated $6.74K.
  • Summit Therapeutics made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #322 holding.
  • E Fund Management (HK) first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.